Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label study comparing the effect of Xeloda [capecitabine] plus intravenous Eloxatin [oxaliplatin] (Xelox) with the standard combination treatment regimen of 5-fluorouracil, folinic acid, and Eloxatin on tumor response in treatment-naive patients with metastatic colorectal cancer

Next Previous
Trial Profile

A randomized, open-label study comparing the effect of Xeloda [capecitabine] plus intravenous Eloxatin [oxaliplatin] (Xelox) with the standard combination treatment regimen of 5-fluorouracil, folinic acid, and Eloxatin on tumor response in treatment-naive patients with metastatic colorectal cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Roche

Most Recent Events

  • 01 Feb 2011 Results published in the International Journal of Cancer.
  • 10 Jan 2008 Status changed from in progress to completed.
  • 09 Feb 2007 ASCO Gastrointestinal Cancer Symposium 2007.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top